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Abstract The serine-proteinase eathepsin G (CG) is a potent SDS-polyacrylamide g l electrophoresis (SDS-PAGE) analy- 
agonist of platelet aggregation inducing the release and surface sis. Each subunit has a modular organization typical of multi- 
expression of c~-granule adhesive proteins such as fihrinogen (Fg) functional adhesive proteins, and contains specific domains 
and thrombospondin-1 (TSP-1). Because Fg and TSP-1 are that support interactions of TSP-1 with cell surface glycopro- 
potential substrates for the enzymatic activity of CG, we tein receptors, sulfated proteoglycans and membrane lipids, 
investigated the fate of these proteins during CG-induced platelet and various matrix proteins [4-7]. Regarding platelet aggrega- 
aggregation using an immunoblot technique. Only a small tion, particular attention has been paid to the amino-terminal 
proportion of secreted Fg was proteolyzed by CG and platelet domain of TSP-1 which contains high-affinity binding site(s) 
aggregation was efficiently inhibited by anti-fibrinogen Fab for heparin, thus commonly designated as the heparin-binding 
fragments. In contrast, TSP-1 was extensively proteolyzed on domain (HBD) [7]. This domain can be cleaved by various 
aggregated platelets releasing in the milieu a fragment with 
M, ~ 28 000, corresponding to the amino-terminal heparin- serine-proteinases, producing a fragment with Mr in the range 
binding domain (HBD). Several antibodies, directed against 25 000-35 000 [7,8]. A role for the HBD in platelet-to-platelet 
the cell-associated earboxy-terminal TSP- l f  fragment interactions i currently supported by the following observa- 
(M, ~ 165 000) impaired the formation of stable macroaggre- tions: (i) some antibodies directed at epitopes within the HBD 
gates, indicating that this fragment may contribute to platelet as well as recombinant HBD polypeptides are potent inhibi- 
aggregation i the absence of the HBD. tots of ct-thrombin-induced platelet aggregation, and can spe- 
cifically inhibit the interaction of purified TSP-1 with ad- 
Key words." Platelet aggregation; Thrombospondin; sorbed fibrinogen [9-11]; and (ii) the recombinant HBD 
Fibrinogen; Cathepsin G; Proteolysis polypeptides directly bind to adsorbed fibrinogen with high 
affinity suggesting that the HBD is a major link between fi- 
brinogen and TSP-1 within the macrocomplex made of the 
1. Introduction two adhesive proteins and their respective membrane recep- 
tor(s) on the surface of activated platelets [I 1]. 
Aggregation of blood platelets following cell stimulation Cathepsin G (CG) is a secretable l ukocyte serine-protein- 
induced by various agonists is a multistep henomenon which ase which activates platelets in the same way as c~-thrombin, 
occurs within seconds [1]. A prerequisite is the binding of including shape change, granular exocytosis and extensive ag- 
fibrinogen to its platelet membrane inducible receptor, the gregation [12-14]. It has been recently reported that CG pro- 
integrin C¢Iib[33 [2]. At this stage, the interaction between fibri- teolyses purified human platelet TSP-1 to a limited extent [15], 
nogen and O~.IIb[~ 3 remains labile, and platelet aggregation fully and CG has also some proteolytic activity on plasma fibrino- 
reversible. Stabilization and 'locking' of this interaction then gen [16]. These observations thus prompted us to investigate 
occur, leading to the formation of irreversible platelet macro- whether CG affects the structure of platelet TSP-1 and fibri- 
aggregates [2,3]. The surface expression of endogenous adhe- nogen expressed on the surface of cells activated by this pro- 
sive proteins tored in platelet ct-granules i thought o play a teinase, and whether modification of these important adhesive 
major role in this latter phenomenon [3]. Based on studies of proteins affects platelet aggregation. 
platelet aggregation i duced by the plasma serine-proteinase 
c~-thrombin, the current concept is that secreted platelet 2. Materials and methods 
thrombospondin (TSP) plays a key role in stabilizing platelet 
interactions initiated by the binding of fibrinogen to  O~iib~ 3 [4]. 2.1. Materials and reagents 
Platelet TSP, or TSP-1, is the prototype member of an Human a-thrombin (2000 U/ms protein), hirudin (1000-3000 U/ms 
emerging family of cell surface and extracellular matrix adhe- protein) from leech, grade V potato apyrase, synthetic prostaglandin 
sive proteins, synthesized and secreted by a number of cell E~ (PGE,), endotoxin-free fraction V bovine serum albumin (BSA) as 
types [4-7]. This large glycoprotein, which has an apparent a 7.5% (w/v) sterile solution, phenylmethylsulfonyl fluoride (PMSF) 
and soybean trypsin inhibitor (SBTI) were purchased from Sigma 
molecular weight (Mr) of 420 000, is composed of three iden- Chemicals Co. (St. Louis, MO, USA). a25I-Protein A (affinity purified, 
tical, disulfide-bonded subunits with Mr ~ 180 000 on reduced 1600 MBq/mg) was from Amersham International p c (Little Chal- 
font, UK). All reagents for SDS-PAGE were from Bio-Rad (Rich- 
*Corresponding author. Fax: (33) (1) 42 49 07 33. mond, CA, USA). Nitrocellulose membranes (0.45 Bm pores) were 
from Schleicher and Schuell (Dassel, Germany). 
Part of this work was presented in abstract form at the XVth Congress CG was isolated from human polymorphonuclear neutrophils ac- 
of the International Society on Thrombosis and Haemostasis, cording to a previously described procedure. The purified enzyme was 
Jerusalem, Israel, June 11-16, 1995. devoid of leukocyte lastase and proteinase 3 activities [17]. 
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Antibodies used in this study were the following: the murine mono- CG at 37°C under stirring, and aggregation and secretion of 
clonal antibody MAII, raised against human platelet TSP-1, reacts cx-granules were followed over time. Whether considering the 
with an epitope located within the Asn 1 Ala 174 sequence of the ami- 
no-terminal HBD [11]. The polyclonal rabbit antibodies designated concentration dependency or the time course of CG-induced 
R3, R6 and R5 are directed against recombinant type 1 (Gly z85 platelet activation, the rate of increase in aggregate formation 
Ile522), type 2 (Pro559-Ile 669) and type 3 (Asp784-Va193~) repeating strictly paralleled that of co-granule xocytosis as measured by 
sequences of human TSP-1, respectively [9]. The immunopurified the secretion of ~-TG (Fig. 1). Under optimal conditions of 
anti-fibrinogen a d control Fab fragments used in functional studies activation by CG (i.e. 20(L400 nmol/l for 5 min), maximal were prepared from rabbit IgG as previously described [18]. For im- 
munoblot analysis, a polyclonal rabbit antibody raised against puri- values for platelet aggregation and a-granule exocytosis 
fled human fibrinogen was obtained from Dako AJS (Copenhagen, were 67.3+4.5 and 92.3+3.8% (mean + S.D., n=12), 
Denmark). The polyclonal IgG fraction obtained from a rabbit anti- respectively, a-Thrombin (0.1 U/ml) was used in parallel as 
serum raised against mouse IgG (RAM/7S) was purchased from Nor- it gave similar values of platelet aggregation and secretion, i.e. 
dic Immunology (Tilburg, The Netherlands). All antibodies were used 
as homogeneous IgG (or Fab)fractions. 70.2+_8.2 and 89.5 + 9.4% (n=9), respectively. Control unac- 
tivated platelets tirred for 5 min at 37°C showed no detect- 
2.2. Preparation of isolated human platelets able aggregation and basal secretion of [3-TG was 9.1 + 1.4% 
Blood anticoagulated with ACD (NIH formula C) was obtained by (n=5) •
venipuncture from healthy adult volunteers. Platelets were then iso- 
lated from plasma by differential centrifugations and fnally resus- 3.2. Cleavage of TSP-1 andfibrinogen during CG-induced 
pended at 3 × 108/ml in Tyrode medium (pH 7.4) containing 2 mM platelet aggregation 
CaC12, 1 mM MgCI2, and 3.5 mg/ml BSA, as detailed previously [9]. 
In order to evaluate the putative proteolytic modifications 
2.3. Platelet aggregation a d secretion of TSP-1 and fibrinogen upon secretion from c~-granules, we 
Platelet suspensions (400 lal) were activated at 37°C under stirring separated the aggregated platelets from the extracellular mi- 
(1100 rpm) in a Dual Aggro-meter (ChronoLog Corp., Havertown, lieu and analyzed these proteins by SDS-PAGE and immuno- 
PA, USA) with 50M00 nmol/l CG or 0.1 U/ml cx-thrombin. When blotting. A representative time-course analysis of the proteo- 
necessary, platelets were preincubated for 1 min with each of the 
various antibodies to be tested, before addition of CG or c~-thrombin, lysis of TSP-1 and fibrinogen during aggregation of platelets 
The variation in light transmission (LT) through the platelet suspen- with 200 nmol/1 CG is illustrated in Fig. 2. Immunoblott ing 
sion was continuously recorded and platelet aggregation expressed as analysis of cell-associated TSP-1 performed under reducing 
a percentage of the maximal variation in LT [19]. At the given time conditions indicated that TSP-1 was rapidly proteolyzed ur- 
points, the enzymic activity of CG was blocked by the addition of 1 
mmol/1 PMSF and 200 gg/ml SBTI [12], whereas cx-thrombin was ing activation (Fig. 2A, left-hand panel), as the intact TSP-1 
blocked by the addition of 1 U/ml hirudin [20]. Platelets were then monomer with an Mr of 180400+-6100 (mean _+ S.D., n=5) 
separated into two 200-gl aliquots: the first aliquot was centrifuged at progressively decreased in intensity, while a cell-associated 
12 000 x g for 3 min, and both the supernatant and pellet were solu- fragment, noted TSP-lf, with Mr = 164 400 + 5000 (n=5) in- 
bilized in the presence of 2% (w/v) SDS and 5 mmol/l N-ethylmalei- creased concomitantly. Densitometric analysis of the autora- 
mide by heating at 100°C for 5 min [17]. Samples were kept at -20°C 
until SDS-PAGE and immunoblot analysis. The second aliquot was diograph shown in Fig. 2 indicated that the conversion of 
mixed with 40 gl of a solution of 0.1 moll1 EDTA to stop exocytosis TSP-1 into TSP-1 f closely paralleled the rates of a-granule 
and centrifuged at 12000×g for 4 min. The supernatant, and an exocytosis and platelet aggregation (indicated at the bottom 
aliquot of the unsedimented platelet suspension, were kept at of the figure), with TSP-lf corresponding to 12, 40, and 81% 
-20°C until they were processed for the measurement of secreted I 3- 
thromboglobulin (13-TG) [19]. This was done using a commercial ELI- of the total TSP-l-reactive material at 1, 3, and 5 min of 
SA (Diagnostica Stago, Asni~res, France) following the manufac- activation, respectively (Fig. 2A, left-hand panel). On seven 
turer's instructions. In selected experiments, the aggregated platelets different platelet preparations, TSP-lf represented 85 +- 6% 
(400 gl) were fixed by adding 50 gl of a 5% (v/v) paraformaldehyde (mean + S.D.) of the cell-associated TSP-1 molecules at 5 
solution in the aggregometer cuvette, then deposited onto 8-well strips min of activation, when exocytosis and aggregation were max- 
and observed using phase-contrast optical microscopy. 
imal. The residual intact TSP-1 (= 15% of the initial content) 
2.4. SDS-PAGE and irnmunoblot analysis 
Electrophoretic separation of platelet proteins in SDS-polyacryl- 
amide slab gels was performed according to the procedure of Laemmli 
as adapted by Nurden et al. [21]. Protein disulfide bonds were reduced ~ 1°° / w  40 ' °° IB  ~ 4 0  by heating the samples at 100°C for 5 min in the presence of 5% (v/v) ~ 
2-mercaptoethanol. Separated proteins were electrotransferred onto ~ ao 80 
nitrocellulose membranes and analyzed by immunoblotting as pre- 
viously described [19]. Primary incubation with the monoclonal nti- 0 60 60 
body MAII was followed by a second incubation with a rabbit anti- m,, 
mouse IgG antibody (RAM/7S). Bound immunoglobulins were re- ~,, 
vealed by a final incubation with 125I-Protein A diluted 1/1000 and 
exposure of nitrocellulose membranes on Kodak X-Omat MA films ~ 20 20 
(Kodak-Path6, Marne-la-Vall6e, France). The extent of proteolysis of o_ 
one given protein was quantitated by densitometric s anning of auto- 0 0 , , , 
radiographs, performed using an LKB Ultroscan XL densitometer 100 200 300 400 0 2 4 6 8 
(LKB-Produkter AB, Bromma, Sweden) equipped with a 633 nm laser CG CONCENTRATION (nmoles/L) TIME OF ACTIVATION (min) 
beam. Fig. 1. Concentration dependency and time course of CG-induced 
platelet exocytosis and aggregation. Platelets (3 x 10S/ml) were incu- 
bated in an aggregometer cuvette at 37°C under stirring for 5 min 
3. Results with increasing concentrations of CG (A), or with 200 nmol/1 CG 
for increasing periods of time (B). At the end of incubation, meas- 
urements were performed for the extent of cell aggregation (D), and 
3.1. Activation ofplatelets by cathepsin G secretion of 13-TG (11), as described in Section 2. Each point is the 
Platelets were activated with increasing concentrations of mean + S.E.M. of 2-4 experimental values. 
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Platelets Extracellular milieu remained largely incomplete by 5 min both on the platelet 
Troalrnent: No CG c~Y No CG cd" surface and in the milieu. The major fragments detected 
"time(rain): 5 '1 3 5' 5 5 rl 3 5' 5 were the fl fragment(Mr = 46400+400, n = 3), only detected 
in the milieu, and the f2 fragment (Mr = 44 000 + 2200, n = 4), 
m,~ present with the platelets and in the milieu (Fig. 2C). Of the 
_ _ j ! ~ ~  .~ .~. ~ ~TSP-1  three fibrinogen subunits, Ac~ (Mr = 65600-+4300, n = 4), Bp TSP-lf (Mr = 56 100+ 1700, n = 4), and y (Mr -- 52500+ 1450, 
.............. n = 4), the densitometric signal given by the A(x chain in 
the CG-treated samples, relative to that of the control non- 
B t~11 i I J  I treated samples, was decreased by ~ 30% at 5 min of activa- 
~ ~  tion, while those given by the B[3 and y chains were un- 31 -<CG-HBD changed. As for CG-aggregated platelets, ~ 50% of secreted 
21. fibrinogen was retained on ct-thrombin-aggregated platelets 
(Fig. 2C). There was no detectable proteolysis of this adhesive 
C 66.2. 97"4"11 i~~ i ~ i i :  • <:]Aa"~ 7-7 (Mr =102 700 + small percentage of the Y chains was converted into T-Y d i m e r s P r ° t e i n  duri g 1500,plateletn=3),activ tiOnboh onbYtheC~-thr°mbin'platelet surfaceand and°nlyain 
: :N~ 1 the milieu. 
f2  
3.3. Effects of anti-TSP-1 and anti-fibrinogen antibodies on 
~TG secreted (%): 7.5 10 40 90 95 CG-induced platelet aggregation 
Aggrega~n(%): 0 27 45 62 74 Since the TSP-lf fragment was the only one to be retained 
Fig. 2. Immunoblot analysis of the proteolytic activity of CG on se- on CG-aggregated platelets, we evaluated its role in support- 
creted TSP-1 and fibrinogen. Platelets were treated with 200 nmol/1 ing platelet-to-platelet in eractions. For this, we tested a panel 
CG for 1 to 5 rain, or with 0.1 U/ml ct-thrombin or with no pro- of polyclonal antibodies directed against he TSP-lf fragment, 
teinase for 5 rain. After sedimentation f the platelets (see Section designated R3, R5, and R6 [9], on CG-induced aggregation of 
2), proteins from the platelets (10 lag) or from the corresponding several platelet preparations. Results of a typical experiment 
volume of milieu were solubilized by SDS in the presence of 5% 2- 
mercaptoethanol and separated by SDS-PAGE on 7% (A,C) or 10% are shown in Fig. 3. As compared to a nonimmune rabbit 
(B) acrylamide gels. Proteins transferred onto nitrocellulose mere- IgG, these antibodies were found to inhibit CG-induced pla- 
branes were probed with the following antibodies: anti-TSP-1 R5 telet aggregation (Fig. 3A). The main effect was a decrease in 
(A), anti-TSP-1 MAII followed by RAM/7S (B), anti-fibrinogen IgG the size of the aggregates formed as shown by the reduction in 
(C), all used at 10 lag/ml. Bound immunoglobulins were revealed by 
incubation with 125I-Protein A, followed by autoradiography. The amplitude of the oscillations in the aggregometer tracings. 
percentages of ]3-TG secretion and cell aggregation measured for Examination of the aggregates by light microscopy confirmed 
this particular experiment are indicated at the bottom, that large platelet aggregates were not formed in the presence 
of these antibodies (Fig. 3B). In contrast, the monoclonal 
can be considered mostly as nonsecreted molecules, on the antibody MAII that reacts with the HBD of TSP-1 had no 
basis that the maximal release of [3-TG was ~ 90%. effect on CG-induced platelet aggregation. 
A fraction of the total TSP-lf generated uring activation By comparison, the anti-fibrinogen Fab fragments pro- 
of platelets by CG was also recovered in the extracellular duced almost total inhibition of platelet aggregate formation 
milieu, particularly at the later time points (Fig. 2A, right- (Fig. 3A). 
hand panel). Thus, based on densitometric analysis, 
48_+ 12.5% of the total TSP-lf fragment was in the superna- 4. Discussion 
tant at 5 min (mean _+ S.D., n--6). Conversion of the TSP-I 
monomer into TSP-lf was accompanied by the generation of Formation of platelet macroaggregates is clearly dependent 
a smaller fragment with Mr=28200 + 1450 (n=3), which was upon exocytosis and surface expression and organization of 
identified as the amino-terminal HBD (CG-HBD) since it was fibrinogen and TSP-1 [3,4]. Thus, using a-thrombin as the 
recognized by the monoclonal antibody MAil [7] (Fig. 2B). agonist, it was originally shown that TSP-1 stabilizes the bind- 
The most striking feature, however, was that, being generated ing of fibrinogen to its membrane receptor, the Cqlb133 integrin 
during the course of platelet exocytosis and aggregation, the [4]. Recent studies have indicated that the amino-terminal 
CG-HBD was almost entirely released into the extracellular heparin binding domain (HBD) of TSP-1 may interact with 
milieu, with only traces (<5%) detected in the cell extracts membrane-bound fibrinogen [9,11], whereas there is also a 
(Fig. 2B). These data were compared to those obtained role for other domains of TSP-1 in platelet aggregation 
when platelets were activated for 5 min with 0.1 U/ml c~- [9,22,23]. 
thrombin. In this case, the bulk of TSP-1 remained associated Cathepsin G is another potent platelet agonist [12-14,24] 
with the cell surface, and compared to the control sample, which can induce extensive cell exocytosis and aggregation, 
there was no evidence for an c~-thrombin-dependent pro eoly- even in the absence of exogenously added fibrinogen ([17] 
sis (Fig. 2A). Immunoblotting analysis of fibrinogen in the cell and this study). This study is so far the first to focus attention 
extract and extracellular milieu performed under reducing on the role of secreted adhesive proteins, namely fibrinogen 
conditions indicated that ~ 50% of secreted fibrinogen re- and TSP-1, in CG-induced platelet aggregation considering 
mained associated with the platelet surface during aggregation the fact that, once secreted from e~-granules, these are poten- 
induced by CG (Fig. 2C). Proteolysis of the secreted fibrino- tial substrates for the enzymatic activity of CG [15,16]. A 
gen appeared to be much less efficient than that of TSP-I as it major role of secreted fibrinogen in CG-induced aggregation 
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Fig. 3. Effects of anti-TSP-1 and anti-fibrinogen a tibodies on CG-induced platelet aggregation. I A, platelets were tested for aggregation i - 
duced by 400 nmol/1 CG, following a 1 min preincubation with the anti-TSP-1 monoclonal murine IgG MAII (0.2 mg/ml), or with the anti- 
TSP-1 polyclonal rabbit IgG R3, R6 or R5 (0.4 mg/ml), or with the anti-fibrinogen rabbit IgG Fab fragments (1mg/ml). Control platelet sus- 
pensions received buffer, nonimmune rabbit IgG (0.4 mg/ml) or Fab fragments (1mg/ml). In B, platelets aggregated for 5 min with 400 nmol/l 
CG in the absence or presence of R~ were fixed with 0.5% (v/v) paraformaldehyde and photographed under microscopy observation. 
is apparent from our observation that anti-fibrinogen Fab effect on CG-induced platelet aggregation. In addition, we 
fragments are potent inhibitors of this aggregation. In agree- have demonstrated in this study that the TSP-lf carboxy- 
ment with these data, previous reports have indicated that terminal fragment which remains associated with the platelet 
CG-activated platelets express the active conformation of surface is functionally active. This is shown by the potency of 
the CtiZb~la fibrinogen receptor [13,24]. As previously suggested several antibodies directed against his fragment to limit the 
from coagulation assays [16], we have shown that CG has size of the aggregates formed. Whether the TSP-lf fragment 
some fibrinogenolytic a tivity, which is, however, rather lim- interacts with fibrinogen or other plasma membrane compo- 
ited under the conditions used in our experiments, especially nent(s) on CG-activated platelets remains to be determined. 
for the membrane-bound fibrinogen (see Fig. 2C). Late during In conclusion, we have shown here that extensive and stable 
CG-induced aggregation, a limited fraction (~ 30%) of the platelet aggregation can occur with CG despite the fact that a 
Atx chains of cell-associated fibrinogen is cleaved, most likely major functional domain of the TSP-1 molecule (i.e. the 
within the carboxy-terminal region which is known to be HBD) is rapidly removed from the cell surface by this pro- 
highly susceptible to early proteolytic attack by various serine teinase. In a more general aspect, the potential capacity of 
proteinases [25]. secretable leukocyte serine proteinases such as elastase [26] 
A major observation in our study is that TSP-1 is very and CG (this study) to proteolyze TSP-1 on the surface of 
efficiently proteolyzed as soon as it is released from the ct- cells where it can be expressed, or in the extracellular matrices 
granules of CG-activated platelets. Proteolysis generates a where it is incorporated [6], could be an important pathway in 
fragment with Mr ~ 28 000, and a partially degraded TSP-1 the regulation of its biological activities in various physio- 
remnant made of polypeptide chains with Mr~ 165000 pathological situations. 
(TSP-lf). This pattern of cleavage, similar to that reported 
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situ by CG, and almost totally absent from the cells at the 
time macroaggregates have formed and stabilized (see Fig. 
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a major role in platelet aggregation i duced by ct-thrombin 
[9,11] appears not to be essential for platelet aggregation i - [1] Gear, A.R.L. (1994) Can. J. Physiol. Pharmacol. 72, 285 294. 
duced by CG, as also indicated by the fact that MAII had no [2] Marguerie, G.A., Ginsberg, M.H. and Plow, E.F. (1987) in: 
86 S. Rabhi-Sabile t al./FEBS Letters 386 (1996) 82~6 
Platelets in Biology and Pathology III (MacIntyre, D.E. and [15] Hogg, P.J., Owensby, D.A. and Chesterman, C.N. (1993) J. Biol. 
Gordon, J.L. eds.) pp. 95-125, Elsevier, Amsterdam. Chem. 268, 21811-21818. 
[3] Kinlough-Rathbone, R.L., Perry, D.W., Mustard, J.F., Dejana, [16] Schmidt, W., Egbring, R. and Havemann, K. (1975) Thromb. 
E., Cazenave, J.-P., Packham, M.A. and Harfenist, E.J. (1983) Res. 6, 315-326. 
Thromb. Hemost. 49, 162-167. [17] Pidard, D., Renesto, P., Berndt, M.C., Rabhi, S., Clemetson, 
[4] Silverstein, R.L., Leung, L.L.K. and Nachman, R.L. (1986) Ar- K.J. and Chignard, M. (1994) Biochem. J. 303, 489498. 
teriosclerosis 6, 245-253. [18] Legrand, C., Dubernard, V., Nurden, A.T. (1987) in: Fibrinogen 
[5] Frazier, W.A. (1991) Curr. Opin. Cell. Biol. 3, 792-799. 2. Biochemistry, Physiology and Clinical Relevance (Lowe, 
[6] Lahav, J. (1993) Biochim. Biophys. Acta 1182, 1 14. G.D.O. ed.) pp. 143 147, Elsevier, Amsterdam. 
[7] Lawler, J., Hynes, R.O. (1987)Semin. Thromb. Hemost. 13, 245 [19] Rabhi-Sabile, S. and Pidard, D. (1995) Thromb. Hemost. 73, 
254. 693-701. 
[8] Raugi, G.J., Mumby, S.M., Ready, C.A. and Bornstein, P. (1984) [20] Tam, S.W., Fenton, J.W. and Detwiler, T.C. (1979) J. Biol. 
Thromb. Res. 36, 165-175. Chem. 254, 8723-8725. 
[9] Legrand, C., Thibert, V., Dubernard, V., B~gault, B. and Lawler, [21] Nurden, A.T., Dupuis, D., Kunicki, T.J. and Caen, J.P. (1981) J. 
J. (1992) Blood 79, 1995-2003. Clin. Invest. 67, 1431-1440. 
[10] Gartner, T.K., Walz, D.A., Aiken, M., Starr-Spires, L. and Ogil- [22] Dixit, V.M., Haverstick, D.M., Henessy, S.W., Grant, G.A., San- 
vie, M.L. (1984) Biochem. Biophys. Res. Commun. 124, 29~295. toro, S.A. and Frazier, W.A. (1985) Proc. Natl. Acad. Sci. USA 
[11] Legrand, C., Morandi, V., Mendelovitz, S., Shaked, H., Hart- 82, 3472 3476. 
mann, J.R. and Panet, A. (1994) Arteriosclerosis Thromb. 14, [23] Tuszynski, G.P., Rothman, V.L., Deutch, A.H., Hamilton, B.K. 
1784-1791. and Eyal, J. (1992) J. Cell. Biol. 116, 209-217. 
[12] Selak, M.A., Chignard, M. and Smith, J.B. (1988) Biochem. J. [24] Molino, M., Di Lallo, M., Martelli, N., De Gaetano, G. and 
251, 293-299. Cerletti, C. (1993) Blood 82, 2442 2451. 
[13] LaRosa, C.A., Rohrer, M.J., Benoit, S.E., Rodino, L.J., Barnard, [25] Doolittle, R.F. in: Haemostasis and Thrombosis (Bloom, A.L. 
M.R. and Michelson, A.D. (1994) J. Vasc. Surg. 19, 306319. and Thomas, D.P. eds.) pp. 163 191, Churchill Livingstone, New 
[14] Si-Tahar, M., Renesto, P., Falet, H., Rendu, F. and Chignard, York. 
M. (1996) Biochem. J. 313, 401~,08. [26] Hogg, P.J., Owensby, D.A., Mosher, D.F., Misenheimer, T.M. 
and Chesterman, C.N. (1993) J. Biol. Chem. 268, 7139-7146. 
